Download image

VM Memantine

Visual representation of the interaction
Mode of action
Memantine
Transporter zone
No interaction
Enzyme zone
No interaction
Receptor zone
Important for clinical effects
Ion channel zone
No interaction

NbN-2 memantine

Molecular structure
NbN_library NH 2
Mode of action
receptor antagonist (NMDA)
Pharmacological target
glutamate
Date published
05.01.2017

Memantine

For more detailed explanation of the principles of the VM Library
For more detailed explanation of the Neuroscience based Nomenclature

Please notice that Caution should be applied when extrapolating animal data to humans.

Detailed and Approved Information on the clinical use of the compounds can be found at the homepage of EMA or at Martindale.

References
  1. Danysz W and Parsons CG. (2012) Alzheimer's disease, beta-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol 167: 324-352.
  2. Bond M, Rogers G, Peters J, et al. (2012) The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess 16: 1-470.
  3. Matsuzono K, Yamashita T, Ohta Y, et al. (2015) Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS). J Alzheimers Dis 46: 687-693.
  4. NbN-2 www.nbn2.com
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country